HUTCHMED and AstraZeneca Submit US NDA for ORPATHYS Plus TAGRISSO
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
targeted therapy
Advertisement
HUTCHMED Initiates Global Phase I Trial of HMPL-A830
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 28, 2026 HUTCHMED (China) Limited announced the initiation of the...
SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer
NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...
Iterion Therapeutics Reports Positive Tegavivint Phase 1b Data
Houston, Texas, U.S., September 22, 2026 Iterion Therapeutics has announced promising results from a Phase 1b clinical study evaluating...
Nuvation Bio IBTROZI Label Updated With Long-Term Data
New York, New York, September 17, 2026 Nuvation Bio Inc. has announced that the U.S. Food and Drug Administration...
Advertisements
Circle Pharma Raises $92.5M to Advance CID-165
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Circle Pharma, Inc. announced an oversubscribed $92.5 million Series E financing...
Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer
Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...
J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
GSK’s Jideytro Shows 94% Response in ROS1 Lung Cancer
London, United Kingdom, September 13, 2026 GSK has announced positive registrational data from the Phase I/II ARROS-1 trial supporting...
AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Advertisement
